These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Matter L; Germann D; Bally F; Schopfer K Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781 [TBL] [Abstract][Full Text] [Related]
3. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination. Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717 [TBL] [Abstract][Full Text] [Related]
5. Type 1 diabetes and measles, mumps and rubella childhood infections within the Italian Insulin-dependent Diabetes Registry. Ramondetti F; Sacco S; Comelli M; Bruno G; Falorni A; Iannilli A; d'Annunzio G; Iafusco D; Songini M; Toni S; Cherubini V; Carle F; Diabet Med; 2012 Jun; 29(6):761-6. PubMed ID: 22133003 [TBL] [Abstract][Full Text] [Related]
6. Trend of measles, mumps, and rubella incidence following the measles-rubella catch up vaccination in the Republic of Korea, 2001. Choe YJ; Eom HE; Cho SI J Med Virol; 2017 Sep; 89(9):1528-1531. PubMed ID: 28303592 [TBL] [Abstract][Full Text] [Related]
7. Spatiotemporal distribution and determinants of measles incidence during a large outbreak, Italy, September 2016 to July 2018. Andrianou XD; Del Manso M; Bella A; Vescio MF; Baggieri M; Rota MC; Pezzotti P; Filia A Euro Surveill; 2019 Apr; 24(17):. PubMed ID: 31039836 [TBL] [Abstract][Full Text] [Related]
8. Surveillance and vaccination coverage of measles and rubella in Northern Italy. Amendola A; Bubba L; Piralla A; Binda S; Zanetti A; Pariani E; Ranghiero A; Premoli M; Pellegrinelli L; Coppola L; Gramegna M; Baldanti F; Zanetti A Hum Vaccin Immunother; 2015; 11(1):206-13. PubMed ID: 25483537 [TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel. Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446 [TBL] [Abstract][Full Text] [Related]
10. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India. Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206 [TBL] [Abstract][Full Text] [Related]
12. Measles, mumps, rubella prevention: how can we do better? Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442 [TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India. Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764 [TBL] [Abstract][Full Text] [Related]
14. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Edmunds WJ; Gay NJ; Kretzschmar M; Pebody RG; Wachmann H; Epidemiol Infect; 2000 Dec; 125(3):635-50. PubMed ID: 11218214 [TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Mossong J; Putz L; Schneider F Epidemiol Infect; 2004 Jan; 132(1):11-8. PubMed ID: 14979584 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013. Plans P; de Ory F; Campins M; Álvarez E; Payà T; Guisasola E; Compte C; Vellbé K; Sánchez C; Lozano MJ; Aran I; Bonmatí A; Carreras R; Jané M; Cabero L Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1161-71. PubMed ID: 25666082 [TBL] [Abstract][Full Text] [Related]
17. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. Amela C; Pachón I; de Ory F Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626 [TBL] [Abstract][Full Text] [Related]
19. When, and how, should we introduce a combination measles-mumps-rubella (MMR) vaccine into the national childhood expanded immunization programme in South Africa? Cameron NA Vaccine; 2012 Sep; 30 Suppl 3():C58-60. PubMed ID: 22939023 [TBL] [Abstract][Full Text] [Related]
20. Utility of serological screening for measles, mumps and rubella in immunocompromised patients. Sticchi L; Astengo M; Iavarone IG; Icardi G Hum Vaccin Immunother; 2019; 15(12):2854-2855. PubMed ID: 31442102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]